BioMedNewsBreaks — BioAdaptives, Inc. (OTC: BDPT) Launches MyndSystem Cognitive Support Platform 

BioAdaptives (OTC: BDPT) a science-driven health and wellness company, announced the launch of MyndSystem, a dual-phase cognitive support platform combining its daytime MyndMed formula with newly released nighttime recovery product MyndRenew into a 24-hour stimulant-free cognitive support system. The company said MyndSystem was originally developed for professional combat athletes and is designed to address both daytime mental performance and overnight neural recovery.

MyndMed is a 12-ingredient daytime formula intended to support focus, mental clarity and cognitive endurance, while MyndRenew is a 14-ingredient nighttime formula designed to support the brain’s overnight repair processes, according to the company. BioAdaptives said the complete MyndSystem platform is now available for purchase as a 30-day supply through direct purchase or subscription.

To view the full press release, visit https://ibn.fm/IcFYg

About BioAdaptives, Inc.

BioAdaptives, Inc. develops and markets science-based health and wellness products for human and animal use. Its formulations are rooted in published research across nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.

For more information, please visit our website at www.bioadaptives.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition 

Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing…

23 minutes ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first…

4 hours ago

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program 

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager…

4 days ago

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Announces Term Sheet for CAD$5 Million Private Placement

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…

5 days ago

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advances ONC010 Manufacturing Development With Nanosoft

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…

5 days ago

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence.…

6 days ago